Transdermal Patch Market & Pipeline Insight 2015

Technological progress is continuously increasing allowing pharmaceutical companies to develop newer products with higher pharmacological benefits. Transdermal patches are extension of their continuous efforts due to which several patients have been able to improve quality of life. This market segment has yet to be tapped as only few disease indications are being covered under their treatment. Pharmaceutical companies are increasing their investments in research and development segment to introduce novel products in market. Significant progress has been made in past several decades giving rise to presence of myriad of products in global market. They are far better than their predecessors and coming products are expected to be better than existing transdermal patches. As a result, more number of patients are expected to be opting for transdermal patches in their therapeutic regime.

Utilization of transdermal patch varies from region to region due to which their market is diffused in nature. In both industrially developed and under developed countries their consumption is increasing significantly in past few years. US is one of the largest transdermal patch market across the globe followed by Europe. Investment in research and development allows the continuous entry of new products in US market due to which it has largest market shares across the globe. It is pioneer in this field and first patch was introduced in 1979 to treat motion sickness after its wide spread acceptance patches for angina, high blood pressure and hormone replacement therapy were introduced in US market. Over the year newer categories like smoking cessation, pain management, Parkinson’s disease, Alzheimer’s disease, ADHD and may others disease indications were added resulting in increased market size.

Download Report:

https://www.kuickresearch.com/report-Transdermal-Patch-Market-&-Pipeline-Insight-2015.php

Clinical pipeline for transdermal patches is becoming strong and various novel therapeutics are at different stages of clinical trials which would enter in market in coming years. It is happening because pharmaceutical companies have identified their commercial potential due to which they are investing more toward research and development segment. Orally administrated drugs are not suitable for all patients as they have gastric reflex problem or may have other gastrointestinal diseases due to which bioavailability is limited. On the other, in blood they may interact with other substance causing reduced pharmacological effects. All these problems are not encountered by patients using the transdermal patches.

New principles are being deciphered and increasing emphasis on including more diseases treatment by transdermal patches is imperative for better health. Owing to increasing disease incidences, it has become necessary to take necessary steps to introduce innovative transdermal patches in global market. Oncology and autoimmune diseases are still untouched by them due to which significant opportunities are left untapped. Technological advancements may allow the investigators to develop products having high safety and efficacy levels along with minimized side effects but it will take some time. On the other hand, nicotine patches and female contraceptive patches are highly developed and forms largest categories of transdermal patch segment. Disease indications will be increased in coming years and advancements in polymer science is expected to increase the innovation rates. With all these developments, the future of transdermal patch market seems to be optimistic.

“Transdermal Patch Market & Pipeline Insight 2015” Report Highlights:

* Mechanism of Transdermal Patch Drug Delivery
* Global Transdermal Patch Market Outlook
* Transdermal Patch Clinical Pipeline by Company, Indication & Phase
* Transdermal Patches in Clinical Pipeline: 93
* Marketed Transdermal Patches: 51
* Global Transdermal Patch Market Future Prospects

For Report Sample Contact: neeraj@kuickresearch.com or

visit: https://www.kuickresearch.com

Recent Publications:

* Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022
* Global CAR T Cell Therapy Market & Clinical Trials Insight 2022
* Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023
* Global Microcapsules Drug Delivery Market Opportunity Outlook 2022
* Global Controlled Drug Delivery Market & Clinical Trial Outlook 2022
* Global Cancer Antibody Drug Conjugates Market & Pipeline Insight 2022
* Global B Cell Lymphoma Market & Clinical Pipeline Insight 2022

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.